You searched for "dysfunction"
The PROMIS trial – time for multi-parametric MRI before a first prostate biopsy
Whilst the relatively random process of 12 core transrectal ultrasound guided (TRUS) prostate biopsy remains by far the most widely employed approach to prostate cancer diagnosis in the UK, its flaws as a standalone diagnostic strategy are increasingly apparent. TRUS-biopsy...
PSA screening in limbo: how low should we go?
One may wonder how the management of prostate cancer could have evolved differently if it had followed a path similar to breast cancer. In breast cancer, early detection in the 1970s relied heavily on imaging because no reliable circulating biomarker...
Are standard repeat biopsies during active surveillance for prostate cancer still necessary?
Active surveillance (AS) has emerged as a key strategy for managing low-risk prostate cancer (PCa), offering an alternative to immediate treatment. Initially, AS relied on prostate specific antigen (PSA) testing, digital rectal examinations (DRE), and systematic biopsies. Early studies using...
A new treatment algorithm for ureteral fibroepithelial polyps in children
Fibroepithelial polyps are rare in the urinary tract (found in 0.5% of all paediatric pyeloplasties and 5% of all cases of paediatric ureteral obstruction). The advent of ureteroscopy in paediatrics has increased the identification and treatment of these. This paper...
BPH therapy: how to find one’s way through the maze?
This communication is from the Young Academic Urologists (YAU) group of the European Association of Urologists (EAU). A purpose-built questionnaire of current practice was sent to 2000 members, of which 637 responded (68% were aged 50 or younger). Alpha blockers...
Campbell-Walsh-Wein Handbook of Urology
Campbell’s Urology, as it is widely referred to, has the unassailable position of being the go-to reference text for urology. Incredibly, this is now available in a concise pocket version! It’s remarkable how such a vast quantity of information could...
Active surveillance for intermediate-risk prostate cancer
In this review, Klotz and Dall’Era summarise available data from the Toronto, UCSF, ERSPC, PASS and Royal Marsden active surveillance cohorts, looking specifically at outcomes of patients classed as intermediate risk. Cancer specific survival in men managed initially with active...
Sepsis and antibiotics: the debate goes on
Sepsis statistics are staggering around the world. The UK Sepsis Trust estimates that there are around 150,000 cases of sepsis in the UK every year and it kills 44,000 patients per year. There are many different definitions and criteria; in...
